Supernus Pharmaceuticals Q2 Revenue Rises 27.7% to $211.3 Million, Beating Estimates

Earnings
โดย Yahoo Finance·US·Read original
Summary · why it matters

Supernus Pharmaceuticals reported second-quarter revenues of $211.3 million, up 27.7% year on year and exceeding analysts' expectations by 2.8%, as the broader group of 9 branded pharmaceuticals stocks tracked reported a strong quarter with revenues beating consensus estimates by 6.6% as a group. The company said full-year operating income guidance exceeded analysts' expectations and full-year revenue guidance slightly topped them, prompting President and CEO Jack Khattar to cite the continued strength and sustained momentum of its growth products and continued execution on its commercial strategy. Despite the beat, Supernus shares are down 5.9% since reporting and currently trade at $41.99. Among peers, Bristol-Myers Squibb reported revenues of $12.97 billion, up 5.7% year on year and 12.9% above expectations, while Corcept Therapeutics posted revenues of $256.1 million, up 31.7% and 21.6% above estimates, the biggest beat and highest full-year guidance raise of the group. Zoetis delivered the weakest performance, with revenues of $2.47 billion, flat year on year and 1.5% below expectations, alongside a significant miss of full-year EPS guidance estimates.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 4 stocks
Supernus Pharmaceuticals Inc
SUPN
▲ PositiveCapitalrelevance

Supernus reported Q2 revenues of $211.3M, up 27.7% YoY and beating estimates, with full-year operating income and revenue guidance topping expectations.

Corcept Therapeutics Incorporated
CORT
▲ PositiveCapitalrelevance

Corcept Therapeutics posted revenues of $256.1M, up 31.7% and 21.6% above estimates, the biggest beat and highest guidance raise of the group.

Health Care▼ · 1 stocks
Zoetis Inc
ZTS
▼ NegativeCapitalrelevance

Zoetis delivered the weakest performance with revenues flat YoY and 1.5% below expectations, plus a significant miss of full-year EPS guidance.

© 2026 MarketDXNews